8.2 Lactation

Risk Summary

There are no data on the presence of mavorixafor in human or animal milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise females that breastfeeding is not recommended during treatment with XOLREMDI and for three weeks after the final dose.

8.3 Females and Males of Reproductive Potential

XOLREMDI is expected to cause fetal harm when administered to pregnant women _[see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]_.

Pregnancy Testing

Verify the pregnancy status in females of reproductive potential prior to initiating XOLREMDI _[see Use in Specific Populations (8.1)]_.

Contraception

Advise females of reproductive potential to use an effective form of contraception during treatment with XOLREMDI and for three weeks after the final dose _[see Use in Specific Populations (8.1)]._
